Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Werewolf Therapeutics Inc
(NQ:
HOWL
)
4.960
+0.070 (+1.43%)
Streaming Delayed Price
Updated: 10:43 AM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Werewolf Therapeutics Inc
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 03, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
April 23, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
April 05, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
April 04, 2024
PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel...
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 07, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
March 06, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
March 05, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
January 08, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
January 04, 2024
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
November 22, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
November 03, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
October 31, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124
September 11, 2023
Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in Upcoming Investor Conferences
September 05, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Participate in May Investor Conferences
May 01, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research
April 19, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 23, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
March 16, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
March 15, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
February 24, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
November 10, 2022
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences
November 07, 2022
From
Werewolf Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.